Use of interleukin-2 in patients with acquired immunodeficiency syndrome

H. Clifford Lane, Jay P. Siegel, Alain H. Rook, Henry Masur, Edward P. Gelmann, Gerald V. Quinnan, Anthony S. Fauci

Research output: Contribution to journalArticlepeer-review

62 Scopus citations


Twelve patients with acquired immunodeficiency syndrome were treated with a natural product, highly purified human interleukin-2. Doses ranged from 250 to 250,000 units. No clinical responses were seen. Minimal toxicity was noted and consisted of mild prolongation of partial thromboplastin time and proteinuria. Immunologic changes during the study included a decrease in the number of circulating T8 lymphocytes, increased skin test reactivity, and a decline in serum immunoglobulin levels.

Original languageEnglish (US)
Pages (from-to)512-516
Number of pages5
JournalJournal of Biological Response Modifiers
Issue number5
StatePublished - Oct 1984
Externally publishedYes


  • Acquired immunodeficiency syndrome
  • Immunomodulation
  • In vivo immune status
  • Interleukin-2
  • Toxicity

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Use of interleukin-2 in patients with acquired immunodeficiency syndrome'. Together they form a unique fingerprint.

Cite this